( Data Also Show Nebivolol Lowers Blood P...)Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy,Health

CHICAGO, May 21, 2007 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. today presented positive data from two clinical studies and one pooled analysis of nebivolol, a selective beta 1-blocker with vasodilating properties currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hypertension. Data from the two clinical studies show that nebivolol demonstrates blood pressure lowering effects as long-term therapy either alone or in combination with other agents, and also as part of a combination treatment for hypertension. The pooled analysis of three registration monotherapy trials supports nebivolol's blood pressure lowering effects for the treatment of hypertension in obese individuals, a difficult- to-treat patient population. The data were presented at the American Society of Hypertension, Inc. (ASH) 22nd Annual Scientific Meeting and Exposition (ASH 2007) in Chicago.

    


    Data presented at ASH includes:


    -- "Long-Term Exposure to the Novel Beta-Blocker Nebivolol as Monotherapy

       or Combination Therapy: Antihypertensive Efficacy and Safety" by

       Vasilios Papademetriou, MD, Professor of Medicine, Georgetown

       University.  [Poster Presentation, P-419: Monday, May 21 from 12 pm to

       1 pm (Riverside Hall)]


       The long-term treatment effects of nebivolol were evaluated in a

       multicenter, 9-month extension study (n=845) of patients who

       successfully completed one of the three randomized, double-blind,

       placebo-controlled registration studies.  Patients received nebivolol

       monotherapy (5 mg, 10 mg, or 20 mg once daily) or nebivolol plus

       adjunct therapy (open-label diuretics or amlodipine).  Outcomes

       demonstrated that nebivolol treatment produced sustained blood pressure

       reductions for the duration of the study period and was well tolerated


'"/>




Page: 1 2 3 4 
Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule
Therapeutic Clinical Trial Results Presented at the 34th Annual
Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at
European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American
Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for
Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data
Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.
Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating
MacroVascular Outcomes Presented at the American Diabetes
Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.
Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin
Conjugate Data Presented at American Diabetes Association Annual
Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in
Hypertensive Patients With Type 2 Diabetes